Pharsight

Janssen Pharms patents expiration

1. Invega Hafyera patents expiration

INVEGA HAFYERA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693 JANSSEN PHARMS Dosing regimen for missed doses for long-acting injectable paliperidone esters
Apr, 2036

(12 years from now)

US11324751 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

US11304951 JANSSEN PHARMS Dosing regimens associated with extended release paliperidone injectable formulations
May, 2041

(17 years from now)

US11666697 JANSSEN PHARMS Methods for ensuring resuspension of paliperidone palmitate formulations
Nov, 2041

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by ad...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA HAFYERA before it's drug patent expiration?
More Information on Dosage

INVEGA HAFYERA family patents

Family Patents

2. Invega Sustenna patents expiration

INVEGA SUSTENNA's oppositions filed in EPO
INVEGA SUSTENNA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(7 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's drug patent expiration?
More Information on Dosage

INVEGA SUSTENNA family patents

Family Patents

3. Invokamet patents expiration

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(10 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 6 months from now)

US11576894 JANSSEN PHARMS Combination therapy for the treatment of diabetes
Jul, 2030

(6 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

4. Invokamet Xr patents expiration

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound
Jul, 2024

(10 months from now)

US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 6 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

5. Invokana patents expiration

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(3 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(1 year, 6 months from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, do...

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

6. Levaquin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6806256 JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Feb, 2022

(1 year, 7 months ago)

US6806256

(Pediatric)

JANSSEN PHARMS Taste masked liquid pharmaceutical compositions
Aug, 2022

(1 year, 1 month ago)

Drugs and Companies using LEVOFLOXACIN ingredient

Market Authorisation Date: 21 October, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of LEVAQUIN before it's drug patent expiration?
More Information on Dosage

LEVAQUIN family patents

Family Patents

7. Ponvory patents expiration

PONVORY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(1 year, 1 month from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(1 year, 1 month from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(2 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents

8. Spravato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2027

(3 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(9 years from now)

US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(10 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

US11311500 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
NCE* (NCE*) Mar 5, 2024
New Indication (I) Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally...

Dosage: SPRAY;NASAL

How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage

SPRAVATO family patents

Family Patents

9. Xarelto patents expiration

XARELTO's oppositions filed in EPO
XARELTO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(1 year, 1 month from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(1 year, 5 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(1 year, 7 months from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(10 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(15 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 23, 2024
M (M) Mar 10, 2023
Pediatric Exclusivity (PED) Sep 10, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic